John W Longshore
Overview
Explore the profile of John W Longshore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shyu J, Schlag P, Karwowska S, Manohar C, Truong H, Longshore J, et al.
PLoS One
. 2023 Dec;
18(12):e0292251.
PMID: 38096164
Objective: To present the technical verification and clinical validation of the companion diagnostic assay, cobas® EZH2 Mutation Test (cobas EZH2 Test), targeting gain-of-function EZH2 mutations in follicular lymphoma (FL) and...
2.
Moreira A, Ocampo P, Xia Y, Zhong H, Russell P, Minami Y, et al.
J Thorac Oncol
. 2020 Jun;
15(10):1599-1610.
PMID: 32562873
Introduction: A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a set of histologic criteria associated with...
3.
Sholl L, Hirsch F, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, et al.
J Thorac Oncol
. 2020 Jun;
15(9):1409-1424.
PMID: 32522712
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with...
4.
5.
McDermott J, Symanowski J, Livasy C, Greger G, Longshore J
J Am Soc Cytopathol
. 2019 May;
3(3):165-169.
PMID: 31051741
Introduction: We present a retrospective analysis of our high-risk human papillomavirus (hr-HPV) test performance using SurePath samples, and we compare these results to published results from Kaiser Permanente of Northern...
6.
Buttner R, Longshore J, Lopez-Rios F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al.
ESMO Open
. 2019 Feb;
4(1):e000442.
PMID: 30792906
Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours. However, there is a need for the development of predictive biomarkers that...
7.
Longshore J, DeMartin K, Yu K, Das P, Zhang G, Rehage T, et al.
J Thromb Thrombolysis
. 2018 Oct;
47(1):87-95.
PMID: 30284176
Laboratory testing for thrombophilia is complicated but essential for diagnosis. In 2017, the cobas® Factor II and Factor V Test (cobas F2F5 test) was launched for use with the cobas...
8.
Buttner R, Gosney J, Skov B, Adam J, Motoi N, Bloom K, et al.
J Clin Oncol
. 2017 Oct;
35(34):3867-3876.
PMID: 29053400
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non-small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing. Nivolumab and...
9.
10.
Levy B, Chioda M, Herndon D, Longshore J, Mohamed M, Ou S, et al.
Oncologist
. 2015 Sep;
20(10):1175-81.
PMID: 26330460
The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly...